Latest News

Liudmila Zhaunova on a global Flo app study linking higher physical activity to lower perimenopause symptom burden.

The 16-item Perimenopause Symptom Scale showed strong reliability and validity among 1255 women aged 35 to 59 years in the United States.

Risa Kagan, MD, on bone health prevention in primary care and why baseline bone density testing should come before age 65.

Patients with 3 or more adverse pregnancy outcomes had lower odds of postpartum contraceptive use in a PRAMS analysis of 222,412 individuals.

Risk factors cast a wide net in preeclampsia prediction, but biomarkers could add precision, according to Dallas Reed, MD.

Risa Kagan, MD, on why the menopause transition is a critical window for bone loss and how women can preserve bone mass.

This FAQ summarizes a Special Report discussion on testosterone pellet therapy in women and advice for hesitant prescribers.

In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.

Mental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD.

This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.

This FAQ summarizes a Special Report discussion of what the evidence does and does not establish about testosterone therapy in women.

Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.

HRSA will award up to $1 million to a single organization to update the Women's Preventive Services Guidelines through the new WISH program.

Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.

Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.

CMS' proposed G-codes, which experts stated would cause confusion in combination with the AMA's proposed codes, were not included in the final fee schedule for 2027, according to ACOG.

Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.

Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.

Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.

Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.

A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.

Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.

The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.

A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.

Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.

The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.

Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.

Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.

Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.

ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.

Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.